Best Adjunctive Therapy for Worsening Depression with Well-Controlled Anxiety

Primary Recommendation: Psychological Adjunctive Treatment

The World Health Organization (WHO) recommends problem-solving treatment as adjunct treatment to ongoing pharmacotherapy in moderate and severe depression, prioritizing non-pharmacologic augmentation when anxiety symptoms are already controlled 1, 2, 3
The WHO guidelines recommend problem-solving treatment as adjunct therapy in moderate and severe depression, providing the strongest guideline-level support for this approach 1, 2, 3

Cognitive behavioral therapy (CBT), including behavioral activation, represents an equally strong first-line adjunctive psychological intervention for moderate to severe depression in patients already on medication 1, 2, 3
Interpersonal therapy may also be considered as adjunctive psychological treatment if resources and trained providers are available 1, 2, 3

Bupropion SR augmentation demonstrated similar efficacy to other augmentation strategies in the STAR*D trial, with lower discontinuation rates due to adverse events (12.5%) compared to buspirone (20.6%) 4
Aripiprazole augmentation is FDA-approved for adjunctive treatment in unipolar, nonpsychotic depression and showed superior remission rates (55.4%) compared to bupropion (34.0%) in one trial, though this study had high risk of bias 4

Since anxiety is already well-controlled, avoid benzodiazepines or anxiolytic-focused augmentation strategies that could introduce unnecessary sedation or dependence risk without addressing the primary problem of worsening depression 1, 2, 3
Buspirone augmentation showed similar efficacy to bupropion in STAR*D but had higher discontinuation rates (20.6% vs 12.5%) due to adverse events 4

Advice on physical activity and relaxation training may be considered as adjunct treatment in moderate and severe depression, though these should supplement rather than replace primary adjunctive interventions 1, 2, 3

Assess treatment response at 4 weeks and 8 weeks using standardized validated instruments to monitor both depressive symptoms and ensure anxiety remains controlled 5
If little improvement occurs after 8 weeks despite good adherence, consider adding a pharmacologic intervention to the psychological adjunctive therapy or switching the augmentation strategy 5
Monitor for symptom relief, side effects, adverse events, and patient satisfaction at each assessment point 5

Do not add benzodiazepines or increase anxiolytic medications when the primary problem is worsening depression with controlled anxiety—this addresses the wrong target symptom 1, 2, 3
Avoid waiting beyond 8 weeks to adjust ineffective adjunctive treatment, as prolonged inadequate response worsens outcomes and increases chronicity risk 5
Do not use antidepressant monotherapy switching as first-line when augmentation is indicated—the evidence from STAR*D showed similar efficacy between switch and augmentation strategies, but augmentation preserves any partial response to the current regimen 4
Failing to use standardized instruments for monitoring makes it impossible to objectively determine treatment response and leads to delayed intervention adjustments 5

The 2023 American College of Physicians guideline found that various augmentation strategies (bupropion, buspirone, cognitive therapy) showed similar efficacy in STAR*D, with moderate certainty evidence, and bupropion had superior tolerability compared to buspirone 4